rrd24757_28666.html

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Eek8r8M5xubwuLbmqXIa4pi9o583UxaC7oX90qw0oVwDzPj1s87utLX/vAkie2eW 2u79hGsh+xgp2AjmYjac9Q== 0001181431-04-010200.txt : 20040217 0001181431-04-010200.hdr.sgml : 20040216 20040217180519 ACCESSION NUMBER: 0001181431-04-010200 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20040207 FILED AS OF DATE: 20040217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SINGER DAVID B CENTRAL INDEX KEY: 0001240366 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-10824 FILM NUMBER: 04610889 MAIL ADDRESS: STREET 1: C/O GENESOFT PHARMACEUTICALS INC STREET 2: 7300 SHORELINE COURT CITY: S SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GENOME THERAPEUTICS CORP CENTRAL INDEX KEY: 0000356830 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 042297484 STATE OF INCORPORATION: MA FISCAL YEAR END: 0831 BUSINESS ADDRESS: STREET 1: 1OO BEAVER ST CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 7813982300 MAIL ADDRESS: STREET 1: 100 BEAVER STREET CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: COLLABORATIVE RESEARCH INC DATE OF NAME CHANGE: 19920703 3 1 rrd33072.xml X0201 3 2004-02-07 0 0000356830 GENOME THERAPEUTICS CORP GENE 0001240366 SINGER DAVID B 100 BEAVER STREET WALTHAM MA 02453 1 0 0 0 Common Stock 398552 D Common Stock 16965 I See Footnote Common Stock 238100 I See Footnote Stock Option (right to purchase) 1.18 2004-02-07 2010-12-13 Common Stock 84823 D Stock Option (right to purchase) 1.18 2004-02-07 2010-12-13 Common Stock 42411 D Stock Option (right to purchase) 1.18 2004-02-07 2010-12-13 Common Stock 42411 D Stock Option (right to purchase) .07 2004-02-07 2013-02-10 Common Stock 633123 D Stock Option (right to purchase) .07 2004-02-07 2013-02-10 Common Stock 250724 D Convertible Promissory Note 6.6418 2004-02-07 2009-02-06 Common Stock 15056 D Held by the Singer-Kapp Family 2000 Trust, over which Mr. Singer has control. Held by the Singer-Kapp Long-Term Trust, over which Mr. Singer has control. Manny J. Bougoulas, Corporate Controller, by Power of Atty 2004-02-16 EX-24. 3 rrd24757_28666.htm POWER OF ATTORNEY rrd24757_28666.html

POWER OF ATTORNEY

I hereby constitute and appoint each of Manny Bougoulas and Edy Mahoney,
signing singly, my true and lawful attorney-in-fact to:

(1) execute for and on my behalf, in my capacity as an officer and/or director
of Genome Therapeutics Corporation (the "Company"), Forms 3, 4 and 5 in
accordance with Section 16(a) of the Securities Exchange Act of 1934 and the
rules thereunder;

(2) do and perform any and all acts for and on my behalf that may be necessary
or desirable to complete and execute any such Form 3, 4 or 5 and timely file
such form with the United States Securities and Exchange Commission and any
stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be to my benefit,
in my best interest, or that I am legally required to do, it being understood
that the documents executed by such a ttorney-in-fact's discretion.

I hereby grant to each such attorney-in-fact full power and authority to
do and perform any and every act and thing whatsoever requisite, necessary, or
proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as I might or could do if
personally present, with full power of substitution or revocation, hereby
ratifying and confirming all that such attorney-in-fact, or such attorney-in-
fact's substitute or substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted. I
acknowledge that the attorneys-in-fact, in serving in such capacity at my
request, are not assuming, nor is the Company assuming, any of my responsibilities to comply with Section 16 of the Securities Exchange Act of
1934.

This Power of Attorney shall remain in f ull force and effect until I am no
longer required to file Forms 3, 4 and 5 with respect to my holdings of and
transactions in Company securities, unless I earlier revoke it in a signed
writing delivered to the attorneys-in-fact.

IN WITNESS WHEREOF, I have caused this Power of Attorney to be executed as
of this 10th day of February 2004.

                                                        /s/ David B. Singer
                                         &n bsp;              __________________
                                                           David B. Singer
                                                Chairman, Genome Therapeutics Corp.

-----END PRIVACY-ENHANCED MESSAGE-----